Cen · FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2022 · Preclinical mechanistic study and transcriptomic meta-analysis · n=>450

Human and mouse muscle transcriptomic analyses identify insulin receptor mRNA downregulation in hyperinsulinemia-associated insulin resistance.

Cited 33 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench and in vitro cell culture experiments combined with animal studies and cross-sectional human transcriptomic meta-analysis

PubMed 34921686 · doi:10.1096/fj.202100497RR · record verified 2026-08-29

What was done

Authors performed a transcriptomic meta-analysis across >450 human skeletal muscle samples examining the correlation between fasting insulin and INSR mRNA. To establish causality, C2C12 mouse myotubes were exposed to elevated insulin for 16 hours followed by 6 hours of serum starvation to assess acute AKT and ERK signaling. Global RNA-sequencing was conducted to evaluate pathway alterations, followed by in vitro and in vivo assessments of Insr gene expression, surface INSR, and total INSR protein, alongside RNAi knockdown to identify transcriptional regulators.

What was found

Fasting insulin negatively correlated with INSR mRNA in human muscle (exact correlation values not stated in the abstract). In C2C12 myotubes, hyperinsulinemia attenuated acute AKT and ERK signaling and altered INSR, FOXO, and glucose metabolism pathways. Hyperinsulinemia substantially reduced Insr gene expression, surface INSR, and total INSR protein both in vitro and in vivo. Bioinformatic modeling and RNAi identified SIN3A as a negative regulator of Insr mRNA, and JUND, MAX, and MXI as positive regulators of Irs2 mRNA.

Why it matters

This study shows that hyperinsulinemia is not merely a passive compensatory response to insulin resistance but can actively drive receptor downregulation in muscle. Elucidating this regulatory pathway identifies potential mechanistic targets to break the cycle of type 2 diabetes progression.

Limits

The abstract provides no exact numerical values, effect sizes, or confidence intervals. Causality and mechanistic pathways were defined in mouse cells and in vivo animal models rather than human interventional trials, limiting direct clinical translation.

Cited by